Semaglutide and lean-mass research

Main paper reviewed; supplements not reviewed. Exploratory model changes are not percentages of cognitive improvement. Possible unblinding and underpowered mediation analyses limit claims about direct brain effects independent of weight loss. Detailed safety counts were not supplied by this secondary analysis.

Semaglutide was open-label. DXA lean mass is not a direct measure of skeletal-muscle volume; lean-mass preservation does not establish improved function.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

This was a planned interim analysis of the first 800 participants in an ongoing 1197-patient trial planned for 240 weeks.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Permanent treatment discontinuation was more frequent with semaglutide, most commonly because of gastrointestinal disorders.

This was a post-hoc pooled analysis across trials with different entry populations and semaglutide doses.

The abstract reports an early-stop recommendation following a planned interim analysis.

This was a pooled analysis of two trials with defined obesity-related HFpEF eligibility, which limits interpretation outside that population.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Semaglutide was open-label and served as a reference, not a powered superiority comparator. Rapid escalation, short treatment, and 15.9% adverse-event discontinuation with survodutide limit interpretation.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

This was a small phase 2 trial with 32 weeks of follow-up; the authors called for larger, longer phase 3 studies.

The trial enrolled a relatively small group, and gastrointestinal adverse events were more frequent with semaglutide.

Gastrointestinal adverse events were more frequent with semaglutide, and cholelithiasis occurred only in that group.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

The active-drug comparison was unblinded. Semaglutide allowed dose reduction for intolerance; liraglutide required stopping, with an option to restart.

The trial used an open-label design.

The authors called for further research to determine whether the findings persist over time.

Only participants who reached the maintenance dose during the initial treatment period were randomized.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Gastric emptying was measured indirectly by paracetamol absorption. This result does not rule out delayed emptying earlier in treatment or under other conditions. Lunch intake is not total daily intake.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

No author-stated limitation was included in the abstract. Week-52 weight data were available for 93% of participants, and participants and investigators knew the target dose despite being masked to treatment assignment.

The study was open-label. Gastrointestinal disorders were the most common reason for discontinuation, and six fatalities occurred across the four groups.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

This prescription-based observational comparison cannot establish equal safety in all surgical patients. Several outcomes were uncommon, reducing precision.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

The authors call for randomized trials to clarify the role of these medicines in asthma.

This was an observational on-treatment study with substantial treatment discontinuation, so it cannot establish comparative causal effects.

Indirect, sponsor-reported comparison, not a head-to-head trial of these doses. Estimates assume continued treatment without additional glucose-lowering medication. Cross-trial differences may remain. Full poster and comparative safety were not reviewed; findings should not be generalized to people without diabetes.

Sponsor-reported indirect comparison, not randomization between these treatments. Results depend on the estimand, how treatment discontinuation is handled. Residual cross-trial differences may remain. Full poster not reviewed; comparable discontinuation does not establish equivalent overall safety.

The small, two-site, ethnically limited study could not separate direct drug effects from skeletal adaptation to weight loss or assess fracture outcomes.

Gastrointestinal adverse events occurred in 80% of semaglutide participants versus 46% with placebo. The trial population excluded people with type 2 diabetes.

The observational single-institution design cannot establish causality, and the authors called for further study.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Recommendations combined graded evidence with expert consensus; some guidance was created despite limited supporting literature.

The guideline states that no disease-targeted drug could then be recommended for the cirrhotic stage.

Trial-product discontinuation was increased with semaglutide and rose as BMI class decreased.

The extension was exploratory and included a subset of treatment completers. Both medication and lifestyle intervention were discontinued.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

The authors caution that consumer-directed third-party testing captures only a small fraction of the safety profile relevant to people injecting these preparations.

Evidence for tirzepatide and CagriSema in adolescents remained limited. The authors call for longer-term, comparative and paediatric safety studies.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

The authors rated evidence certainty very low for every outcome because of imprecision and indirectness.

Searches covered selected date windows and the pipeline search was updated through June 4, 2022. This synthesis is not one comparative trial, and the authors emphasized scarce long-term outcome evidence.

This was retrospective and compared two compounded-drug programs paired with behavioral support. Association does not prove that dose alone caused the difference, and the abstract does not report weight-loss outcomes.

A single case cannot establish comparative effectiveness. The authors call for studies comparing the result with intensified GLP-1 therapy.

A single case cannot establish neuropathy reversal or distinguish a direct drug effect from improved metabolism. The unchanged symptoms are an important limit.

The proposed care framework is expected to change as long-term outcome data become available. It should not be read as new experimental proof for combining the medicines.

Long-term studies are still needed to establish durability, safety and effects on major liver-related clinical outcomes.

Detection bias and obesity-related confounding affect the risk signals. Further prospective research specific to cancer subtype is needed.

Different study methods and a lack of direct comparisons prevented formal drug ranking. Psychological outcomes were infrequently assessed.

No direct trial of resistance exercise during incretin therapy is presented; the exercise recommendation is the authors’ proposal, so preservation during treatment remains untested here.

The abstract gives no review-selection methods, study counts, or formal quality assessment. Its statement that early pipeline data may exceed tirzepatide is not a head-to-head finding, so methodological quality remains unassessed.

The review notes that maintaining long-term weight loss is difficult.

This is a mechanistic review, not a comparative clinical trial. The authors identify disease heterogeneity and divergent drivers as obstacles to finding broadly effective treatments; no author-stated methodological limitation appears in the abstract.

This was a review, not one randomized trial. Cardiovascular analyses had few events, and the added contribution of GIP-receptor agonism remained uncertain.

This was a broad review rather than a comparative intervention trial, and the abstract did not provide quantitative efficacy or safety outcomes.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Independent evaluation of usability, recognition accuracy, medication understanding, adherence and clinical effects is needed.

The study was still in progress; comparative effectiveness results were not yet presented.

These mouse experiments do not establish weight-maintenance benefits in humans. The abstract does not report adverse-event results.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

This was mechanistic preclinical research. It does not establish the same neural effects, weight response or safety in humans, and methodological quality was not appraised.

This abstract provides preclinical pharmacology, not evidence of human effectiveness or safety; semaglutide was still in phase 3 testing at publication.